Salute e Benessere
Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
"We are honored to welcome Josephine and Joe to our Board," said , Co-Founder and Executive Chairman of Continuity Biosciences. "Josephine's regulatory acumen and clear-eyed judgment are second to none. Joe is not only a visionary in drug delivery but also a trusted partner in our efforts through Focal Medical and PinPrint. Their expertise will be instrumental as we continue to scale our programs and build long-term value."
Torrente and DeSimone join Continuity's existing Board of Directors, which includes and , , (Continuity's co-founders), , , , and .
Founded in 2024, Continuity Biosciences is developing advanced delivery platforms for biologics and complex therapeutics, with a focus on and . Operating in Houston (TX), Raleigh (NC), Bradenton (FL), and Torino ( Italy ), Continuity's pipeline spans oncology, metabolic diseases, infectious diseases, and women's health. Through strategic acquisitions—including Focal Medical—and targeted investments like PinPrint, Continuity is building a differentiated platform to transform the delivery of challenging therapeutics.
Logo - https://mma.prnewswire.com/media/2555793/Continuity_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/continuity-biosciences-appoints-josephine-torrente-and-joseph-desimone-phd-to-board-of-directors-302522793.html